Matrix Metalloproteinase 14 promotes lung cancer by cleavage of Heparin-Binding EGF-like Growth Factor()()

Molecularly targeted therapies benefit approximately 15–20% of non-small cell lung cancer (NSCLC) patients carrying specific drug-sensitive mutations. Thus, there is a clinically unmet need for the identification of novel targets for drug development. Here, we performed RNA-deep sequencing to identi...

Descripción completa

Detalles Bibliográficos
Autores principales: Stawowczyk, Marcin, Wellenstein, Max D., Lee, Sharrell B., Yomtoubian, Shira, Durrans, Anna, Choi, Hyejin, Narula, Navneet, Altorki, Nasser K., Gao, Dingcheng, Mittal, Vivek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2016
Materias:
Original article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5198728/
https://www.ncbi.nlm.nih.gov/pubmed/28013056
http://dx.doi.org/10.1016/j.neo.2016.11.005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5198728/
https://www.ncbi.nlm.nih.gov/pubmed/28013056
http://dx.doi.org/10.1016/j.neo.2016.11.005

Ejemplares similares